EUVIMEDEUVIMED entdecken
Crossref

Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial

Mathilde Morisseau, Carlos Gomez-Roca, Marie Viala, Audrey Rabeau, Delphine Loirat, Nadia Munsch, Kristell Thomas, Cécile Pages, Iphigenie Korakis, Vincent Sibaud, Jean-Pierre Delord, Thomas Filleron und 1 weitere

Investigational New Drugs · 2024

DOI: 10.1007/s10637-024-01481-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Investigational New Drugs, 2024. Verfasst von Mathilde Morisseau und 12 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud- IUCT-O, 1 Avenue Irène Joliot-Curie, Toulouse, Cedex 9, 31059, France. Hauptthemen laut MEDLINE: Melanoma. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Bristol-Myers Squibb Foundation for Research in Immuno-Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaHumansFemaleMaleProspective StudiesMiddle AgedNeoplasmsImmune Checkpoint InhibitorsAgedAdverse Drug Reaction Reporting SystemsCarcinoma, Non-Small-Cell LungLung NeoplasmsDrug-Related Side Effects and Adverse ReactionsAdult

Stichwörter der Autor:innen

Adverse events analysisImmune checkpoint inhibitorMOTIVATE trialOncology clinical trialsPrevalence

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud- IUCT-O, 1 Avenue Irène Joliot-Curie, Toulouse, Cedex 9, 31059, France.
  • Department of Medical Oncology, Oncopole Claudius Regaud- IUCT-O, Toulouse, France.
  • Department of Medical Oncology, Institut du Cancer de Montpellier (ICM), Montpellier, France.
  • Department of Pneumology, CHU Toulouse Larrey, Toulouse, France.
  • Department of Medical Oncology, Institut Curie, Paris, Saint-Cloud, France.
  • Department of Drug Development and Innovation (D3i), Institut Curie, Paris, Saint-Cloud, France.

Förderung

  • Bristol-Myers Squibb Foundation for Research in Immuno-Oncology

Zitieren

APA

Morisseau, M., Gomez-Roca, C., Viala, M., Rabeau, A., Loirat, D., Munsch, N., Thomas, K., Pages, C., Korakis, I., Sibaud, V., Delord, J. P., Filleron, T., & Cabarrou, B. (2024). Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01481-9

Vancouver

Morisseau M, Gomez-Roca C, Viala M, Rabeau A, Loirat D, Munsch N, et al. Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial. Investigational New Drugs. 2024. doi:10.1007/s10637-024-01481-9

BibTeX
@article{Morisseau2024,
  author = {Morisseau, Mathilde and Gomez-Roca, Carlos and Viala, Marie and Rabeau, Audrey and Loirat, Delphine and Munsch, Nadia and Thomas, Kristell and Pages, Cécile and Korakis, Iphigenie and Sibaud, Vincent and Delord, Jean-Pierre and Filleron, Thomas and Cabarrou, Bastien},
  title = {Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial},
  journal = {Investigational New Drugs},
  year = {2024},
  doi = {10.1007/s10637-024-01481-9}
}
Kostenlos starten →